The agency has provisionally determined that Selarsdi will be interchangeable with Stelara following the exclusivity ... for ...

Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous ... pharmacokinetics and immunogenicity to the reference drug Stelara® in patients with moderate to severe plaque psoriasis.

It will be available in the same formulations as Stelara, including 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and ...

4%). Results from GALAXI 2/GALAXI 3 found that Tremfya 200 mg demonstrated statistically significant and clinically meaningful superiority to Stelara on all pooled endoscopic endpoints ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.